Monitor the upcoming corporate update call on September 1 for clinical timelines and patient enrollment updates for paxalisib in TNBC and HR+/HER2- breast cancer. The heavy warrant overhang (~4.3M ADSs) combined with recent capital raises (ATM reduction on Aug 28, prior offering) suggests persistent dilution risk; watch for any price-supportive buyback or operational catalysts.
Price Chart
Executive Summary
Kazia Therapeutics closed an oversubscribed, tranched public offering generating approximately $40 million in upfront gross proceeds, with potential for up to $120 million total if milestone-linked warrants are exercised. The capital will fund expansion of paxalisib into new breast cancer and colorectal cancer indications, but the steep immediate dilution (~2.58M ADSs at $15.50/ADS plus pre-funded warrants and up to 4.3M additional ADSs from warrants) overhangs the stock.
Key Financial Metrics
Key Facts
- Closed an oversubscribed offering of 2,580,000 ADSs plus pre-funded warrants, with combined price of $15.50 per ADS and associated warrants.
- Upfront gross proceeds of approximately $40 million; total potential gross proceeds could reach ~$120 million if all milestone-linked warrants are exercised.
- Series A Warrants for 2,243,478 ADSs at $17.825/ADS (15% premium) expire 30 days after Stage IV TNBC data readout (expected H2 2027) or 5-year anniversary.
- Series B Warrants for 2,064,000 ADSs at $19.375/ADS (25% premium) expire 30 days after HR+/HER2- data readout (expected H1 2028) or 5-year anniversary.
- Use of proceeds: clinical development of paxalisib in TNBC, HR+/HER2- breast cancer, and pMMR colorectal cancer, plus working capital.
- Institutional participants include ADAR1 Capital Management, Columbia Threadneedle, Lynx1, Marshall Wace, and Pointillist Family Office.
Financial Impact
Approximately $40 million in upfront gross proceeds from the offering; total potential gross proceeds of ~$120 million if all warrants exercised, with dilutive impact up to ~4.3 million additional ADSs (at current offering unit price of $15.50) beyond the 2.58 million ADSs sold.
Risk Factors
- Significant immediate dilution from 2.58M ADSs plus pre-funded warrants at $15.50/ADS, plus up to 4.3M additional ADSs from Series A and B warrants.
- Milestone-linked warrants may never be exercised if clinical data readouts fail or are delayed, leaving the company with less capital and no share buyback.
- Recent SEC filings show multiple offerings within days (Aug 28 ATM reduction, Aug 31 selling), adding to existing dilution overhang relative to ~$155M market cap.
- Clinical-stage biotech with no approved product — pipeline risk is high; failure in any trial could materially impact the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302865390 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $8.30 (−10.46%) |
Sep 22, 2026 5w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $8.30 (−23.99%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $8.30 (−34.18%) |
Aug 31, 2026 8w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $8.30 (+34.28%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $8.30 (−39.72%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.30 (+39.72%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $8.30 (+39.72%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $8.30 (+38.88%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $8.30 (−38.88%) |
Jul 28, 2026 13w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $8.30 (−34.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers